Agouron sees Viracept protease inhibitor on market in first half of 1997 -- CEO Johnson.
Executive Summary
AGOURON ANTICIPATES VIRACEPT MARKET ENTRY IN FIRST HALF OF 1997, Agouron Pharmaceuticals President and CEO Peter Johnson told the Alex. Brown health care conference in Baltimore. Johnson said the company's protease inhibitor nelfinavir for the treatment of HIV infection has entered pivotal trials and that an NDA will be filed "very early next year."